|
|
|
|
|
|
| Abstract Search | Browse Program and Abstracts | Schedule-at-a-Glance | Conference Mission & Sponsors | Program Committee | Contact Us |
| # | Title |
|---|---|
| 217 | The Investigation of Plasmid DNA Stability in Attenuated Strains of Salmonella
I. V. Dukhovlinov1, Y. N. Dukhovlinova1, B. V. Murashev1, M. N. Boychenko2, N. A. Klimov*1, A. A. Vorobyov2, and A. P. Kozlov1 1Biomedical Ctr., St. Petersburg, Russia and 2I. M. Sechenov Moscow Med. Academy, Russia |
| 218 | Efficiency and Stability of gp120 Incorporation on the Surface of HIV-1 Pseudovirion Particles
J. Hammonds*, X. Chen, and P. Spearman Vanderbilt Univ., Nashville, TN, USA |
| 219 | Coxsackievirus as a Vector for a Therapeutic HIV Vaccine
A.I. Ramsingh* Wadsworth Ctr., New York State Dept. of Hlth., Albany, USA |
| 220 | Immunization with Tat and Rev Induces Partial Protection from Mucosal SHIV Infection in Rhesus Macaques
B. Verrier*, R. Le Grand, C. Coiffier, Y. Ataman, B. Hurtrel, R. Gruters, A.-M. Aubertin, A. Osterhaus, G. Sutter, V. Erfle, B. Vaslin, and M. Girard UMR CNRS-bioMérieux, CERVI, Lyon, France; CEA, Fontenay-aux-Roses, France; Inst. Pasteur, Paris, France; INSERM U 74, Strasbourg, France; GSF Inst. für Biologie, Munich, Germany; and Eramus Univ., Rotterdam, The Netherlands |
| 221 | Comparative Analysis of Expression and Immunogenicity of HIV-1 Group-Specific Antigen Pr55gag by Conventional Plasmid Vectors Versus Semliki-Forest-Virus-Derived Vectors
J. Zhang*1,2 , J. Wild2, K. Bieler2, M. Graf2, L. Deml2, H. Wolf2 , P. Liljeström3, R. Wagner2, and Y. Shao1 1Natl. Ctr. for AIDS Prevention and Control, Chinese Academy for Preventive Med., China; 2Inst. of Med. Microbiology, Univ. of Regensburg, Germany; and 3Microbiology and Tumorbiology Ctr., Karolinska Inst., Stockholm, Sweden |
| 222 | SV40 as a Vaccine Delivery Vector for Immunization against SIV Envelope Glycoprotein
H. McKee* and D. Strayer Jefferson Med. Coll., Philadelphia, PA, USA |
| 223 | Immunization against HIV-1 gp120 using SV40 as a Vaccine Delivery Vector
H. McKee and D. Strayer* Jefferson Med. Coll., Philadelphia, PA, USA |
| 224 | Production of HIV-1 Vaccine Components in Plants
A. V. Karasev*, B. V. Kim, K. J. Shon, and H. Koprowski Thomas Jefferson Univ., Doylestown, PA, USA |
| 225 | Measles Vaccine as a Potential Vector for AIDS Vaccination
F. Tangy*1, C. Combredet1, V. Labrousse-Najburg1, C. Lorin1, F. Delebecque1, Z. Wang2, M. Caballero2, A. Zuniga2, M. Billeter2, H. Naim2, L. Mollet1, H. McClure3, M. Feinberg 3, M. Kazanji4, and H. Contamin4 1Pasteur Inst., Paris, France; 2Univ. of Zurich, Switzerland; 3Emory Univ., Vaccine Res. Ctr., Atlanta, GA, USA; and 4Pasteur Inst., Cayenne, French Guyana |
| 226 | Enhanced HIV-1 Gag Expression and Immunogenicity by an AAV-ITR DNA Plasmid Vector Encoding the Antigen as a Lysosomal Membrane Protein Chimera
E. T. A. Marques, Jr.*, P. Chykhlikar, Y. Lu, J. S. Chen, I. C. Leao, J. T. August, and C. Chougnet The Johns Hopkins Sch. of Med., Baltimore, MD, USA |
| 227 | Improved Adenovirus-Based Gene Delivery Technology for Vaccination
R. Vogels, M. Havenga, D. J. Opstelten, B. Bout, M. Mehtali, and T. Logtenberg* Crucell NV, Leiden, The Netherlands |
| 227a | Filamentous Phage for Producing Antibody Responses Focused against B2.1, an HIV-1 Vaccine Lead Peptide
N. E. van Houten*1, M. B. Zwick1,2, A. Menendez1, P. W. H. I. Parren2, D. R. Burton2, and J. K. Scott1 1Simon Fraser Univ., Burnaby, BC, Canada and 2The Scripps Res. Inst., La Jolla, CA |
| 227b | Hen Eggwhite Lysozyme as a Model Antigen for Producing Epitope-Targeted Vaccines
M.B. Irving*, A. Menendez and J.K. Scott Simon Fraser University, Burnaby, BC, Canada |